IBM has been upgraded to a Strong Buy rating due to the robust performance of its Software segment, especially Systems Software, which drives most of its revenue and profit. Growth in Hybrid Cloud and Automation, supported by Red Hat's competitive edge and increasing enterprise AI adoption, is expected to exceed overall market growth. Despite challenges in AI model weaknesses and limited competitiveness in Application Software, IBM's strategic acquisitions and cloud partnerships help maintain its strong market position.
IBM's software segment is the focus of this update. For readers following the Technology sector, here is Pluang's market snapshot as of Oct 20, 2026 01:32 WIB: Out of 150 US tech stocks, 120 rose and 30 fell. Notable movers include APLD at USD 19.30 with a 6.90% increase, DDOG at USD 261.71 up 5.91%, and TWLO at USD 256.12 up 4.81%, with TWLO showing 100% buy order activity on Pluang.
The Hershey Trust Company sold 1,512 common shares under a trading plan but kept voting control through Class B shares. Hershey will report Q3 earnings on October 29, with investors focused on how price increases affected Halloween-season demand. Q2 ...
W. R. Berkley reported mixed Q3 2026 results with earnings per share of $1.17 beating estimates, but revenue fell short at $3.74 billion versus $3.82 billion expected. The company saw premium growth with gross premiums up 3% and net premiums up 1%, s...
GE Aerospace is set to report its Q3 earnings with analysts forecasting a 21.7% rise in earnings per share to $2.02 and nearly 12% revenue growth to about $12.7 billion. Despite consistently beating estimates, the stock has fallen after past reports ...
Silence Therapeutics' stock surged 125.6% to $19.58 following Merck KGaA's agreement to acquire the RNA-interference drug developer for about $1.3 billion in equity value. Merck will pay $20 per share, a 130% premium over the recent closing price. Ot...
On October 19, 2026, several stocks saw significant declines. Iambic Therapeutics dropped 31.4% but stayed just above its IPO price of $16 after raising $150 million. TCGX Acquisition fell 18.5% following its announcement of a merger with TriGemX Bio...
